Orrstown Financial Services (NASDAQ:ORRF) Downgraded by Zacks Investment Research to Sell

Orrstown Financial Services} stock has undergone multiple analysts rating changes in the recent past.  Orrstown Financial Services Downgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More Orrstown Financial Services (NASDAQ:ORRF) Downgraded by Zacks Investment Research to Sell

Osmotica Pharmaceuticals (NASDAQ:OSMT) Downgraded by Zacks Investment Research to Sell

Osmotica Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Osmotica Pharmaceuticals Downgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More Osmotica Pharmaceuticals (NASDAQ:OSMT) Downgraded by Zacks Investment Research to Sell

PAVmed (NASDAQ:PAVM) Upgraded by Zacks Investment Research to Hold

PAVmed} stock has undergone multiple analysts rating changes in the recent past.  PAVmed Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More PAVmed (NASDAQ:PAVM) Upgraded by Zacks Investment Research to Hold

Processa Pharmaceuticals (NASDAQ:PCSA) Upgraded by Zacks Investment Research to Hold

Processa Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Processa Pharmaceuticals Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Processa Pharmaceuticals (NASDAQ:PCSA) Upgraded by Zacks Investment Research to Hold

PDS Biotechnology (NASDAQ:PDSB) Upgraded by Zacks Investment Research to Hold

PDS Biotechnology} stock has undergone multiple analysts rating changes in the recent past.  PDS Biotechnology Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More PDS Biotechnology (NASDAQ:PDSB) Upgraded by Zacks Investment Research to Hold

Peapack-Gladstone Financial (NASDAQ:PGC) Downgraded by Zacks Investment Research to Hold

Peapack-Gladstone Financial} stock has undergone multiple analysts rating changes in the recent past.  Peapack-Gladstone Financial Downgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

View More Peapack-Gladstone Financial (NASDAQ:PGC) Downgraded by Zacks Investment Research to Hold

Playa Hotels & Resorts (NASDAQ:PLYA) Upgraded by Zacks Investment Research to Buy

Playa Hotels & Resorts} stock has undergone multiple analysts rating changes in the recent past.  Playa Hotels & Resorts Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

View More Playa Hotels & Resorts (NASDAQ:PLYA) Upgraded by Zacks Investment Research to Buy

ProPhase Labs (NASDAQ:PRPH) Upgraded by Zacks Investment Research to Buy

ProPhase Labs} stock has undergone multiple analysts rating changes in the recent past.  ProPhase Labs Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Strong Sell.

View More ProPhase Labs (NASDAQ:PRPH) Upgraded by Zacks Investment Research to Buy

Poseida Therapeutics (NASDAQ:PSTX) Upgraded by Zacks Investment Research to Hold

Poseida Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Poseida Therapeutics Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Poseida Therapeutics (NASDAQ:PSTX) Upgraded by Zacks Investment Research to Hold

PolarityTE (NASDAQ:PTE) Downgraded by Zacks Investment Research to Hold

PolarityTE} stock has undergone multiple analysts rating changes in the recent past.  PolarityTE Downgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

View More PolarityTE (NASDAQ:PTE) Downgraded by Zacks Investment Research to Hold